Skip to main content

Table 2 Overall proportion (low and high estimates) of cases targeted by a quadrivalent or a nonavalent HPV vaccine

From: Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France

   Low estimate High estimate
Invasive cervical cancers (EDITH I) Quadrivalent 69.2 [64.4-73.9] 82.2 [78.5-85.8]
Nonavalent 84.5 [81.0-87.8] 92.1 [89.5-94.3]
Absolute additional Impact* (% of additional prevented cases) 15.3% (p < 0.001) 9.9% (p < 0.001)
Relative additional Impact** 22.1% 12.0%
High-grade cervical neoplasias (EDITH II) Quadrivalent 43.4 [36.9-50.0] 64.7 [59.6-69.9]
Nonavalent 76.7 [72.2-81.0] 89.5 [86.4-92.3]
Absolute additional Impact (% of additional prevented cases) 33.3% (p < 0.001) 24.7% (p < 0.001)
Relative additional Impact 76.6% 38.2%
Low-grade squamous intraepithelial lesions (EDITH III) Quadrivalent 13.6 [5.6-24.1] 33.5 [25.6-41.4]
Nonavalent 25.9 [17.5-35.0] 56.2 [49.8-62.8]
Absolute additional Impact (% of additional prevented cases) 12.3% (p < 0.001) 22.7% (p < 0.001)
Relative additional Impact 90.7% 67.7%
External acuminata condylomata (EDITH IV) Quadrivalent 63.1 [57.3-68.9] 88.2 [84.7-91.4]
Nonavalent 68.6 [63.1-73.8] 90.3 [87.2-93.2]
Absolute additional Impact (% of additional prevented cases) 5.4% (p = 0.095) 2.1% (p = 0.318)
Relative additional Impact 8.6% 2.4%
Anal cancers (EDITH V) Quadrivalent 70.5 [64.7-76.0] 84.7 [80.6-88.7]
Nonavalent 80.9 [76.4-85.1] 93.2 [90.3-95.6]
Absolute additional Impact (% of additional prevented cases) 10.4% (p = 0.001) 8.5% (p < 0.001)
Relative additional Impact 14.7% 10.0%
Oropharyngeal carcinomas (EDITH VI) Quadrivalent 41.4 [33.1-50.0] 42.4 [33.8-51.1]
Nonavalent 41.4 [33.1-50.0] 43.9 [35.5-52.2]
Absolute additional Impact (% of additional prevented cases) 0.0% (NC) 1.6% (p = 0.687)
Relative additional Impact 0.0% 3.8%
  1. *Absolute additional potential impact of the nonavalent vaccine.
  2. **Relative additional potential impact of the nonavalent vaccine.
  3. NC, not calculated.
\